In addition, the lack of significant difference between CHEK2 All heterozygotes and controls in all-cause mortality in individuals with cancer suggests that germline CHEK2-associated cancer is not clinically more aggressive than non-CHEK2-associated cancer. This evidence concerns the gene CHEK2 and cancer.